112575-13-0

Usage

Uses

Used in Organic Synthesis:
6-Bromo-2-N,N-dimethylaminopyridine is used as a reagent in organic synthesis for its ability to catalyze a variety of chemical reactions, including Suzuki-Miyaura cross-coupling reactions and Buchwald-Hartwig amination reactions. Its distinct properties and high reactivity contribute to the efficient synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 6-Bromo-2-N,N-dimethylaminopyridine is utilized as a catalyst in the development of new drugs. Its unique functional groups and catalytic properties enable the synthesis of novel compounds with potential therapeutic applications, contributing to the advancement of pharmaceutical research and drug discovery.

Upstream product

• 626-05-1 2,6-Dibromopyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 19798-81-3 2-Amino-6-bromopyridine 
• 50-00-0 formaldehyd 
• 74-88-4 methyl iodide 
• 144100-07-2 2-bromo-6-fluoropyridine 
• 74-89-5 methylamine 
• 124-40-3 dimethyl amine 

Downstream Products

• 1356336-25-8 N,N-dimethyl-6-(4-(trifluoromethyl)phenyl)pyridin-2-amine 
• 1356336-24-7 4-(6-(dimethylamino)pyridin-2-yl)benzonitrile 
• 1220595-99-2 benzyl 2-(6-(dimethylamino)pyridin-2-yl)ethylcarbamate 
• 1208348-08-6 6-(2-amino-5-methylphenyl)-N,N-dimethylpyridin-2-amine 
• 1208348-07-5 6-(2-aminophenyl)-N,N-dimethylpyridin-2-amine 

Relevant academic research and scientific papers

Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors

Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) regulates the proliferation and differentiation of neuronal progenitor cells during brain development. Consequently, DYRK1A has attracted interest as a target for the treatment of neurodegenerative diseases, including Alzheimer's disease (AD) and Down's syndrome. Recently, the inhibition of DYRK1A has been investigated as a potential treatment for diabetes, while DYRK1A's role as a mediator in the cell cycle has garnered interest in oncologic indications. Structure-activity relationship (SAR) analysis in combination with high-resolution X-ray crystallography leads to a series of pyrazolo[1,5-b]pyridazine inhibitors with excellent ligand efficiencies, good physicochemical properties, and a high degree of selectivity over the kinome. Compound 11 exhibited good permeability and cellular activity without P-glycoprotein liability, extending the utility of 11 in an in vivo setting. These pyrazolo[1,5-b]pyridazines are a viable lead series in the discovery of new therapies for the treatment of diseases linked to DYRK1A function.

THIAZOLE DERIVATIVE AND APPLICATIONS THEREOF

Disclosed in the present invention are a new thiazole compound, particularly a compound represented by formula (I), a pharmaceutical composition thereof and applications thereof in the preparation of drugs for the treatment of diseases related to herpes simplex viruses.

BENZOSULFONYL COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Amination of Aromatic Halides and Exploration of the Reactivity Sequence of Aromatic Halides

A base-promoted amination of aromatic halides has been developed using a limited amount of dimethylformamide (DMF) or amine as an amino source. Various aryl halides, including F, Cl, Br, and I, have been successfully aminated in good to excellent yields. Although the amination of aromatic halides with amines or DMF is usually considered as an aromatic nucleophilic substitution (SNAr) process, and the reactivity of an aromatic halide is F > Cl > Br > I, the reactivity of aromatic halides in this system was found to be I > Br a‰ F > Cl. This protocol also showed a good regioselectivity for multihalogenated aromatics. This protocol is valuable for industrial application due to the simplicity of operation, the unrestricted availability of amino sources and aromatic halides, transition metal-free conditions, no requirement for solvent, and scalability.

PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: Structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1)

The recent discovery of allosteric modulators of the CB1 receptor including PSNCBAM-1 (4) has generated significant interest in CB1 receptor allosteric modulation. Here in the first SAR study on 4, we have designed and synthesized a series of analogs focusing on modifications at two positions. Pharmacological evaluation in calcium mobilization and binding assays revealed the importance of alkyl substitution at the 2-aminopyridine moiety and electron deficient aromatic groups at the 4-chlorophenyl position for activity at the CB1 receptor, resulting in several analogs with comparable potency to 4. These compounds increased the specific binding of [3H]CP55,940, in agreement with previous reports. Importantly, 4 and two analogs dose-dependently reduced the Emaxof the agonist curve in the CB1 calcium mobilization assays, confirming their negative allosteric modulator characteristics. Given the side effects associated with CB1 receptor orthosteric antagonists, negative allosteric modulators provide an alternative approach to modulate the pharmacologically important CB1 receptor.

Regioselective intramolecular electrophilic substitution reactions involving π-deficient pyridine substrates: a new entry to pyridoquinazolines and benzo[h][1,6]naphthyridines

Regioselective intramolecular electrophilic substitution reactions have been described in π-deficient pyridine substrates tethered at C-2 to the aryl amine. The presence and nature of ring activating groups at C-6 led to the involvement of either N-1 or C-3 of the pyridine ring in the cyclization thereby leading to the regioselective synthesis of pyridoquinazolines and naphthyridines in excellent yields.

Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists

A series of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives was synthesized, and their structure-activity relationships were examined in order to identify potent and selective arginine vasopressin V2 receptor agonists. Attempts to substitute other chemical groups in place of the 2-pyridilmethyl moiety of 1a led to the discovery that potent V2 binding affinity could be obtained with a wide range of functional groups. This structural tolerance allowed for the manipulation of other attributes, such as selectivity against V1a receptor affinity or avoidance of the undesirable inhibition of cytochrome P450 (CYP), without losing potent affinity for the V2 receptor. Some representative compounds obtained in this study were also found to decrease urine volume in awake rats.

3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES

The present invention provides 3-indazoyl-4-pyridylisothiazoles or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and methods of using the same, as well as processes for preparing the same, and intermediates thereof.

Nitrile-Stabilized Carboanions. Nucleophilic Substitution Reactions on Bromopyridines

A series of bis(2-heteroaryl)acetonitriles were synthesized, characterized, and transformed into the corresponding bis(2-heteroaryl)methanes, which can be readily oxidized with SeO2 in glacial acetic acid to the respective ketones.These disubstituted acetonitriles are ideal precursors to heterocalixarenes.The configuration in the solid state of meso-cyano compound 16 was ascertained by an X-ray crystal structure.